Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinchai Kanggan Capsule is a Traditional Chinese Medicine (TCM) developed and manufactured by Wuhan Pharmaceutical Valley Technology Development Co., Ltd. It is primarily indicated for the treatment of the common cold and upper respiratory tract infections, particularly those characterized by 'wind-heat' symptoms in TCM theory. The formulation is a multi-ingredient herbal extract typically containing *Lonicera japonica* (Jin Yin Hua), *Bupleurum chinense* (Chai Hu), *Scutellaria baicalensis* (Huang Qin), and *Forsythia suspensa* (Lian Qiao). These components are traditionally recognized for their ability to clear heat, detoxify, and resolve the exterior. Pharmacologically, the capsule exhibits antipyretic, anti-inflammatory, and analgesic properties, helping to alleviate clinical symptoms such as fever, headache, cough, and sore throat. It is approved as a Chinese patent medicine (Zhongcheng Yao) in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinchai Kanggan Capsule.